Biogen's oral dimethyl fumarate shows MS lesion reduction
This article was originally published in Scrip
Biogen Idec's experimental oral drug dimethyl fumarate (BG-12, BG00012) has reduced new gadolinium enhancing inflammatory brain lesions in patients with relapsing-remitting multiple sclerosis (MS) by up to 69% compared with placebo, according to publication of Phase II results in the October 25th issue of The Lancet.
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.